Presymptom Health is a pioneering medtech company that creates diagnostic tests to detect illnesses earlier to help save lives.
Established to exploit a ground-breaking innovation to detect sepsis in patients up to three days before symptoms appear, Presymptom has recently secured nearly £2M of seed funding and support to enable it to conduct its multisite NHS PRECISION clinical trial, which began enrolling in May 2021. The company is developing a clinical diagnostic portfolio that will ultimately include tests for use at both point-of-care and within central laboratory settings.
A team led by Mervyn Singer, Professor of Intensive Care Medicine at University College London, and Dr Roman Lukaszewski, Chief Diagnostic Officer at the Defence Science & Technology Laboratory (Dstl) of the UK Ministry of Defence, has just published the results of a pioneering sepsis study.
Presymptom Health is open to investment discussions to join us on our journey to create a truly revolutionary test for sepsis.
Find out morePresymptom Health has a development plan to extend its clinical diagnostic test portfolio to include tests for both point of care and within central laboratories.
Find out more